AMN Healthcare Services may be trading about 13% below its intrinsic value according to a Discounted Cash Flow analysis, even after a 138.1% year-to-date rally. The DCF model, based on trailing free cash flow of roughly $399.4 million, estimates fair value at around $41.32 per share, implying a 12.9% discount to the current price. The recent second-quarter 2026 results, which included revenue of $673.2 million and net income of $21.2 million, support the cash-flow-based valuation. However, a Fair Ratio model that adjusts for growth, margins, and risk suggests a benchmark P/E of about 2.1 times, making the stock appear overvalued on earnings at its current multiple of 13.3 times. Overall, AMN Healthcare screens as undervalued on three of six valuation measures, leaving a mixed picture.
AMN Healthcare Services IncDCF and Fair Ratio models give mixed valuation signals; Q2 earnings beat supports cash flow but P/E suggests overvaluation.
Dassault Aviation SA